Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Lagercrantz Group AB in connection with its acquisition of Prido AB
Mandate

Vinge advises Lagercrantz Group AB in connection with its acquisition of Prido AB

February 07, 2024 Employment and Benefits Capital Markets and Public M&A IT, Telecommunications and Outsourcing Intellectual Property Data protection and processing of personal data Real Estate and Construction EU, Competition and Regulatory

Vinge advises Lagercrantz Group AB in connection with its acquisition of 96% of the shares in Prido AB. Prido AB was founded in 1973 and is today one of Europe's largest manufacturers of high-quality industrial folding doors, with an annual revenue of approximately SEK 300 million. The transaction is subject to approval by the relevant authorities and is expected to close in March 2024.

Vinge's team consisted of Johan Winnerblad, Clara Sohlberg and Filip Magnusson (M&A), Victor Björkheim (Employment), Ellis Allmark (Agreements), Sofia Bergenståhle (IPR), Johan Cederblad, Karolina Cohrs and Madelene Andersson (Real Estate and environment), Ida Redander (Finance), Alva Chambert (Competition) and Arthur Kinski (IT/GDPR).

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

 Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

 Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026